risks of glp 1 agonists Mapping the effectiveness and GLP-1 receptor - Nature Medicine What is the risk of

Lipo-C formulations are compounded products that haven't been individually reviewed by the FDA, and they're not FDA-approved for weight loss or any specific medical indication

On phase: 3 months of active dosing per cycle

Research conventions cite a 0.5-1 mg once-daily SC loading phase until pigmentation builds, then 1 mg once or twice weekly maintenance

When administered as a treatment of low sexual desire in women, bremelanotide has a favorable safety profile, having completed phase 3 clinical trials prior its being approved for use in the United States in 2019 [15]

Chen O, Michlkov S, Eckhardt L, et al

Important considerations include potential drug interactions and the risk of masking serious complications